ACADIA Pharmaceuticals Inc. vs YieldMax TSLA Option Income Strategy ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.84 (market cap $5.07B), while YieldMax TSLA Option Income Strategy ETF trades at $21.93. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | TSLY | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $29.41 | $48.25 |
52-Week Low | $20.06 | $20.49 |
Enterprise Value | $4.19B | — |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →